11 research outputs found
Adverse events in healthy subjects exposed to single and multiple doses of LY2140023 monohydrate: Pooled results from 10 phase 1 studies
No full text10.1097/JCP.0b013e3182542633Journal of Clinical Psychopharmacology323408-411JCPY
PMH13 Differences Between Patients Undergoing Augmentation or Switching of Antipsychotic Medications During Treatment of Schizophrenia
No full text
Delivering the choice agenda as a framework to manage adverse effects: a mental health nurse perspective on prescribing psychiatric medication
No full textGene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs
No full textAn Agonist–Antagonist Interaction Model for Prolactin Release Following Risperidone and Paliperidone Treatment
No full text
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
No full textObjective: Research and clinical translation in schizophrenia is limited by inconsistent definitions of treatment resistance and response. To address this issue, the authors evaluated current approaches and then developed consensus criteria and guidelines. Method: A systematic review of randomized antipsychotic clinical trials in treatment-resistant schizophrenia was performed, and definitions of treatment resistance were extracted. Subsequently, consensus operationalized criteria were developed through 1) a multiphase, mixed methods approach, 2) identification of key criteria via an online survey, and 3) meetings to achieve consensus. Results: Of 2,808 studies identified, 42 met inclusion criteria. Of thes
Antipsychotic Drug Treatment for Patients with Schizophrenia: Theoretical Background, Clinical Considerations and Patient Preferences
No full text
